Market Size
The global tardive dyskinesia treatment market was valued at USD 3.65 billion in 2025 and is projected to reach USD 6.65 billion by 2033, growing at a CAGR of 12.6% during the forecast period from 2026 to 2033.
The market is witnessing strong growth driven by the increasing prevalence of neurological and psychiatric disorders, rising long-term use of antipsychotic medications, and growing awareness about movement disorders. Improved diagnosis rates and greater recognition of tardive dyskinesia as a serious and treatable condition are significantly contributing to market expansion.
Market growth is further supported by advancements in pharmacological therapies, particularly the development of VMAT2 inhibitors, which have demonstrated significant efficacy in managing symptoms. Pharmaceutical companies are actively investing in novel drug development and expanding clinical pipelines to address unmet patient needs. In addition, regulatory approvals and product clearances from agencies such as the U.S. Food and Drug Administration are enhancing treatment availability and strengthening market access globally. Favorable reimbursement policies and increasing focus on mental health treatment are also accelerating adoption across healthcare systems.
Tardive dyskinesia treatment is evolving with a focus on targeted therapies, improved safety profiles, and long-term disease management strategies. The integration of digital health tools and patient monitoring solutions is enhancing treatment adherence and clinical outcomes. Furthermore, increasing research into neuroprotective therapies and personalized medicine approaches is expanding future treatment possibilities.
Market Scope
| Metrics | Details |
| Market CAGR | 12.6% |
| Segments Covered | By Drug, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Market Dynamics
Prolonged use of antipsychotic drugs by patients will drive this market
Tardive dyskinesia is one of the side effects of antipsychotic medications. Antipsychotic drugs are used to treat schizophrenia and other mental health disorders.TD causes stiff, jerky movements of the face and body that one can't control. The patient might blink their eyes, stick out their tongue, or wave their arms without meaning to do so.
Antipsychotic medications are used as short or long-term treatments for bipolar disorder to control psychotic symptoms such as hallucinations, delusions, or mania symptoms. The severity of TD may fluctuate over time, improve despite continuing antipsychotic exposure, and, in rare cases, spontaneously remit in the medium-to-long term. The cumulative risk of developing TD appears to increase the longer treatment continues. However, TD can also occur after short-term exposure to antipsychotic drugs.
An estimated 16–50% of patients treated with antipsychotics have TD. The cumulative incidence rate is about 4% to 5% annually and the prevalence rate is 20% to 30%. Younger patients are the ones who are at risk and may be particularly susceptible to more generalized and dystonic movements, but older age is a major risk factor.
The increased clinical approvals will drive the tardive dyskinesia market in the forecast period
Researchers have studied several possible treatments for tardive dyskinesia, including vitamins and many different medicines. One of the medications, tetrabenazine, which is approved to treat involuntary movements associated with Huntington's disease, showed promise to treat tardive dyskinesia in small studies.
The FDA has approved valbenazine (Ingrezza), the first drug to treat tardive dyskinesia. Valentine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. TD is likely to remain important in clinical practice and may even increase in prevalence as antipsychotics are expansively marketed. The ideal goals of future research should be the elimination of TD because of antipsychotic treatment and the development of interventions to reverse TD once it occurs. Approval of VMAT2 inhibitors offers an effective treatment to reduce the severity and impact of TD. Many clinical studies are still going on for tardive dyskinesia and will drive the market in the forecast period.
Side effects of drugs lack of awareness about the disorder will hamper the market
Tardive dyskinesia is difficult to diagnose. Symptoms generally do not appear until the medication has been taken for months or years and can first appear after ceasing treatment. If clinically feasible the first-line management of tardive dyskinesia is the withdrawal of antipsychotic medication. Though, for many patients with serious mental illness, the discontinuation of antipsychotics is impossible due to disease relapse. In the part of the disease process, SDs may worsen when antipsychotics are discontinued. TD can worsen during antipsychotic withdrawal as well, in the form of withdrawal dyskinesias.
Neuroleptic drugs are often prescribed for the management of certain mental, neurological, or gastrointestinal disorders. The drugs used for chronic gastrointestinal conditions that may cause tardive dyskinesia are metoclopramide and prochlorperazine. Neuroleptic drugs block dopamine receptors in the brain. Dopamine is a neurotransmitter, a chemical that helps brain cells to communicate. Although in most cases it occurs after a person has taken these drugs for several years, some cases may occur with shorter neuroleptic drugs. ainty, measurement is essential.
Market Segmentation
Valbenazine will dominate the market
Valbenazine is a novel and highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor with an approximate 20-hour half-life and low peak-to-trough concentration ratio which allows once-daily dosing. It is used to treat tardive dyskinesia in adults. Tardive dyskinesia is a neurological disorder characterized by involuntary movements. The clinical trials were six weeks in duration that led to FDA approval of valbenazine.
Valbenazine became the first US FDA-approved medication indicated for the treatment of TD. It is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. The advantages of valbenazine include rapid onset of effect within two weeks of treatment initiation. Ingrezza a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). INGREZZA capsules are used for oral administration only. Each capsule contains 73 mg or 146 mg of valbenazine tosylate equivalent to 40 mg or 80 mg of valbenazine free base, respectively.
The hospital segment will dominate the market in the forecast period
Once TD is detected, a practical management strategy entails a progressive series of steps consistent with standard patient care. Once TD is confirmed, a discussion should occur with patients and caregivers to inform them of the diagnosis, prognosis, and treatment options. Several pharmacological decisions then follow that are not necessarily mutually exclusive. Re-evaluating antipsychotic treatment is the priority.
Patients with antipsychotic dose reductions showed significant increases in both all-cause and mental health-related hospitalizations, suggesting that antipsychotic dose reductions may lead to increased overall healthcare burden in some schizophrenia patients. A hospital setting is best to treat patients with tardive dyskinesia for better treatment. Hence, this segment will see a rise in the market.
Market Geographical Share
North America region will dominate the tardive dyskinesia treatment market
Increasing prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure, and R&D in this region will drive the market.
As incidences of mental illness increase, so too does awareness. Recognition and education are important to remove the stigma that is often associated with mental health concerns. Mental Health Awareness Month helps people realize the many ways in which mental illness touches their own lives and helps them learn about available services, and discover ways to advocate for increased support.
Many Americans with mental illness still lack access to care. States with the lowest workforce populations have, on average, only one mental health professional per 1,000 individuals. However, access to insurance that covers mental health issues is on the rise. Access to actual treatment has also grown.
The prevalence of schizophrenia among U.S adults is estimated to be around 1.5 million people per year. (National Alliance on Mental Illness, 2019). Schizophrenia is often diagnosed in young people during their late teens to early 30s, with symptoms commonly presenting earlier in males than in females. (National Institute of Mental Health, 2018)
U.S. R&D investments are divided approximately into 20% applied research, 16.5% basic research, and the remaining 63.5% in experimental development. Until 2021, the U.S. outspent all other countries in total R&D investments.
Key Developments
February 2026: Growing adoption of VMAT2 inhibitors as first-line therapy significantly improved symptom control and patient outcomes, strengthening their dominance in tardive dyskinesia treatment protocols.
January 2026: Increasing integration of AI-based diagnostic tools and digital screening platforms enhanced early detection rates, reducing the long diagnostic gap associated with tardive dyskinesia.
December 2025: Rising focus on precision medicine and patient-centric care accelerated development of targeted therapies and personalized treatment approaches in neurological disorders.
November 2025: Advancements in formulation technologies, including extended-release and sprinkle-based oral drugs, improved treatment adherence and expanded patient accessibility.
October 2025: Increasing exploration of novel therapeutic targets, such as non-dopaminergic pathways, gene therapies, and neuromodulation techniques, expanded the treatment pipeline.
September 2025: The growing prevalence of psychiatric disorders and long-term antipsychotic use drove demand for effective therapies, supporting steady market expansion globally.
August 2025: Expansion of telehealth and digital health platforms improved patient access to diagnosis and treatment, particularly in remote and underserved regions.
July 2025: Increasing investments in clinical trials and strong pipeline development of next-generation therapeutics enhanced innovation and competitive dynamics in the market.
Market Companies
Some players in the tardive Dyskinesia (TD) Treatment Market include Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Biogen, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, GlaxoSmithKline plc., Bayer AG, Sanofi, Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Key Companies to Watch
Teva Pharmaceutical Industries Ltd
Overview: Teva Pharmaceuticals are developing and producing medicines to help improve people's lives for more than a century. They have been committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in almost every therapeutic area. Around 200 million people around the world take their medicine every day. They are served by one of the largest and complex supply chains in the pharmaceutical industry. Along with an established presence in generics, they have significant innovative research and operations supporting their growing portfolio of specialty and biopharmaceutical products.
Product Portfolio: The company has established a presence in generics. They have significant innovative research and operations supporting their growing portfolio of specialty and biopharmaceutical products.
Key Development: Teva's first DTC campaign for tardive dyskinesia (TD) drug Austedo launches into a suddenly competitive TV ad space for the rare condition. It joins Neurocrine Biosciences, Inc.'s Ingrezza campaign that began in April.
The Tardive Dyskinesia Treatment Market. report would provide an access to an approx. 52 market data table, 42 figures and 200 pages.
